Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evobrutinib effect on QTc interval in healthy adults
NCT07214935Phase 1Completed
- Sponsor
- Merck KGaA
- Start
- Nov 2022
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of evobrutinib in multiple sclerosis (MS), sponsored by Merck KGaA. Primary endpoint: Placebo-corrected Change From Baseline in Corrected QT Interval by Fridericia' Formula for Evobrutinib at 24 hours. Started Nov 2022; status: completed.
02
Drugs
evobrutinib
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT07214935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07214935.